ArticleOncology letters2019

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.

Matthias Villalobos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.